Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C

Michelle D Kelsey; L Kristin Newby

doi:10.7326/J22-0060

Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C

Ann Intern Med. 2022 Aug;175(8):JC86. doi: 10.7326/J22-0060. Epub 2022 Aug 2.

Authors

Michelle D Kelsey¹, L Kristin Newby¹

Affiliation

¹ Duke University, Durham, North Carolina, USA (M.D.K., L.K.N.).

PMID: 35914252
DOI: 10.7326/J22-0060

Abstract

Hao Q, Aertgeerts B, Guyatt G, et al. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. BMJ. 2022;377:e069066. 35508320.

Publication types

Comment

MeSH terms

Anticholesteremic Agents* / therapeutic use
Cardiovascular Diseases* / prevention & control
Cholesterol, LDL
Ezetimibe / therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
PCSK9 Inhibitors
Proprotein Convertase 9

Substances

Anticholesteremic Agents
Cholesterol, LDL
Hydroxymethylglutaryl-CoA Reductase Inhibitors
PCSK9 Inhibitors
PCSK9 protein, human
Proprotein Convertase 9
Ezetimibe